IrelandIreland

More capacities

07.03.2012

Abbott Laboratories is to spend a85m and expand its pharmaceutical manu­facturing facility in Sligo (Ireland), saying that would help the company to ensure its supply of compounds in bio­pharmaceutical areas like virology and nephrology. The investment, which will result in the creation of up to 175 jobs, is supported by the country’s investment promotion agency IDA Ireland. The expansion will be completed in 2014, bringing total employment at the site to 300. Azita Saleki-Gerhardt, president of global pharmaceutical operations at Abbott, said the company has had a presence in Ireland for more than 65 years, and that Sligo is an important part of its pharmaceutical manufacturing network. In total, Abbott runs eight manufacturing facilities in Ireland.

Tech Review

22.08.2011

Outsourcing is one of the biggest global trends in the biopharmaceutical industry. It is taking more and more specific know-how to master the challenges posed by manufacturing of biologics, which include rising price and cost...

Politics / Law

22.08.2011

Brussels – The European Commission has launched the biggest ever call for proposals to fund European research and innovation and said that it will continue to foster health research on the continent. The European Commissioner for...

Politics / Law

22.08.2011

Sussex/Brussels – British experts warn that hospitals in the country’s National Health Service (NHS) are risking being taken to court for carrying out genetic tests based on techniques patented by private companies. Lawsuits...

Politics / Law

22.08.2011

A Our recent contribution in this column (No. 1-2, Vol. 10, 2011) focused on the end of Swiss-type medical use claims in the EPO. According to the EPO decision G2/08, the traditional Swiss-type medical use claim (“Use of...

Politics / Law

22.08.2011

Parma – The European Food Safety Authority has reached a first major milestone in its work on health claims. With the publication of its 6th and final series of evaluation results, the authority finished the scientific assessment...

Politics / Law

22.08.2011

Brussels – As this ‘Heard in Brussels’ is being written, the ‘Heard’ element of my column is fairly ironic, as all you can hear in Brussels in August is the sound of tumbleweeds blowing down empty streets as politicians and their...

Politics / Law

22.08.2011

In the ongoing biofuel debate, probably the only viewpoint every participant shares is that fossil fuels will one day run out, and that a viable alternative needs to be found. In the early days of biofuel production, worldwide...

Politics / Law

22.08.2011

In June, the European Commission presented the first EU certification schemes designed to certify that biofuels marketed in the EU are produced from sustainable resources. The approval of these voluntary schemes is excellent news...

Tech Review

21.08.2011

The pharmaceutical industry and regulatory authorities are facing new challenges in the development of new drugs that have complex interdependencies. Even at the early stage of process development, a number of detailed parameters...

Clinical Trial

21.08.2011

Cambridge (UK) – Muscarinic receptor agonists like pilocarpine demonstrably boost amounts of secreted saliva, and are therefore promising agents for the treatment of xerostomia (dry mouth), a common discomfort following cancer...

Displaying results 101 to 110 out of 1983

< Previous 101-110 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/10/article/more-capacities.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK70.9%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.1%
  • IMMUNICUM AB (S)16.60 SEK-38.1%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP750.0%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-96.0%
  • EVOCUTIS (UK)0.22 GBP-92.3%
  • AGENNIX (D)0.04 EUR-80.0%

No liability assumed, Date: 22.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper